<DOC>
	<DOC>NCT02290431</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.</brief_summary>
	<brief_title>Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient has a previous diagnosis of multiple myeloma Patient requires retreatment for multiple myeloma Patient has measurable M component in serum or urine at study screening Primary refractory disease (patients that never reached at least an minor response for over 60 days under any prior therapy) Patient who has been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose Patient received prior treatment with DAC inhibitors including panobinostat Patient has impaired cardiac function, or a prolonged QTc interval at screening ECG Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LBH589,</keyword>
	<keyword>panobinostat,</keyword>
	<keyword>bortezomib,</keyword>
	<keyword>dexamethasone,</keyword>
	<keyword>Phase II</keyword>
</DOC>